Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1445544

Cover Image

PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1445544

Genital Warts Assessment, By Drug Type, By Treatment, By Route of Administration, By End-user, By Region, Opportunities and Forecast, 2017-2031F

PUBLISHED:
PAGES: 221 Pages
DELIVERY TIME: 3-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel Printable (Single User License)
USD 4500
PDF & Excel Printable (Corporate License)
USD 5700
PDF & Excel Printable (Custom Research License)
USD 8200

Add to Cart

Description

Table of Contents

List of Tables

Global genital warts market is projected to witness a CAGR of 4.79% during the forecast period 2024-2031, growing from USD 2.01 billion in 2023 to USD 2.92 billion in 2031. The genital warts market is experiencing growth due to rising numbers of HPV cases, particularly in adults. In addition to government initiatives, advancing technology and efforts of R&D are also fueling the market greatly. HPV is seen to drastically rise in population all over the globe, leading to a rise in several genital warts cases as well. Technology is also advancing in terms of improved solutions to disease. The vaccine for HPV gives the body enough immunization to not let warts or other such STDs happen. The government is playing a major role in spreading awareness about getting vaccinations to avoid getting such diseases in the first place. Giving free vaccines in schools, and camps, and organizing rallies and camps to spread awareness are some of the government initiatives, which are offering lucrative market opportunities.

In Canada, a statement was passed by the Minister of Health, the Minister of Mental Health and Addictions, and the Associate Minister of Health on Human Papillomavirus Prevention Week. It stated that vaccination is one of the best methods to avoid cancer and genital warts. The HPV vaccination is available at no cost through school-based clinics, public health clinics, or catch-up programs. It is advised for 9 to 14-year-olds as part of their usual vaccination schedule.

The efforts underway to reach the national goal of 90% immunization among Canadian youth by 2025 are heartening. 84% of 14-year-olds received an HPV vaccination in 2021, a considerable increase in males' HPV vaccination rates over the two years prior. Even if this objective can be attained, it is crucial to keep advocating for and supporting HPV vaccination for all kids.

Increasing Prevalence of Genital Warts

Throughout the world, one of the most prevalent STDs is the genital warts caused due to human papillomavirus (HPV). While most HPV infections are benign and go away on their own, some virus strains can cause genital warts and several kinds of cancer. The global market for genital warts is expanding rapidly because of the growing interest in the creation of diagnostic instruments, vaccinations, and therapies due to the rising prevalence of HPV-related illnesses, including genital warts. Mortality rates have decreased because of early discovery and treatment made possible by routine screening with Pap smears and HPV testing. Highly contagious genital warts are known to be caused by HPV strains 6 and 11. They may not be fatal, but they can cause discomfort and reduce one's quality of life. The market for associated disorders with HPV, such as genital warts, is expected to increase significantly in the future as creative approaches to treating HPV-related illnesses become more and more in demand. There is hope that we may reduce the prevalence of such diseases and improve people's general health and well-being globally through ongoing research, immunization campaigns, and public awareness initiatives.

According to a study that was published in 2023 by The Lancet Global Health, nearly one in three men over the age of 15 have at least one genital human papillomavirus (HPV) type infection, and one in five have one or more of the high risks, or oncogenic, HPV kinds. These estimates highlight the significance of collaborative efforts to manage HPV infection and reduce the prevalence of HPV-related disease in both men and women. Such efforts are anticipated to increase market demand.

Technological Advancements

Better indication detection, treatment, and prevention have long been made possible by technological improvements in the healthcare sector. One such field is the treatment of diseases linked to the human papillomavirus (HPV), such as genital warts, where technology is having a big influence. Growing technological improvements have been a major factor in driving the global genital warts market in recent years. Developing more precise and accessible screening methods is one of the main ways that technology improvements are impacting the genital warts business. The main tools for identifying HPV and the disease associated with it have historically been Pap smears and HPV DNA testing. But more recent technologies have also surfaced, like molecular diagnostics and liquid-based cytology. The use of liquid-based cytology facilitates the identification of anomalies.

Conversely, molecular testing finds the virus' genetic makeup and yields more accurate results. These advanced screening techniques not only increase diagnosis accuracy, but also provide faster results. The development of vaccinations that specifically target HPV strains has been made possible by developments in molecular biology and genetic sequencing. The development of the HPV vaccination has revolutionized the fight against cervical cancer, genital warts, and other related conditions. The goal of ongoing research and development is to increase the effectiveness of vaccines and increase their use.

Teva Pharmaceuticals launched the first generic version of Absorica (isotretinoin) in April 2021, intended to treat severe, resistant nodular acne genital warts. Oral isotretinoin is an effective therapy option for patients with resistant facial plane genital warts.

Topical Treatment Method is Dominating the Global Market

Over the course of the projection period, the topical treatment segment is expected to grow at a rapid rate. Topical treatment is successful in managing HPV infections. They provide patients with an all-encompassing approach to medical therapy by treating the underlying virus as well as the symptoms. These treatments work by destroying the warts and stimulating the body's immune system to fight the virus. Some commonly used topical treatments include imiquimod, podofilox, and sinecatechins. Imiquimod is an immune response modifier that stimulates the body's immune system to attack the virus and is applied directly to the affected area.

In March 2020, Verrica Pharmaceuticals Inc. and Torii Pharmaceutical Co., Ltd. announced a collaboration and licensing agreement to create and commercialize product candidates, such as VP-102, for a topical cantharidin formulation intended to treat molluscum contagiosum and common genital warts in Japan.

North America to Dominate Genital Warts Market

With the biggest market share in terms of value, North America has emerged as the leading force in the global genital warts industry. The high incidence of HPV in the region is one of the main causes of North America's market domination in genital warts. Particularly in the United States, there is a significant HPV burden, with millions of new cases reported yearly. Due to the high prevalence, there is a sizable market for HPV-related goods and services due to the increasing demand for HPV diagnostic tests, vaccinations, and treatment options. Modern hospitals, cutting-edge diagnostic tools, and a highly qualified medical workforce are all part of North America's well-developed healthcare infrastructure. Efficient screening, diagnosis, and treatment of illnesses linked to HPV are made possible by this infrastructure. Moreover, with the state-of-the-art medical treatments and technologies, North America is the top choice for patients looking for HPV-related healthcare services that may include treatment of genital warts, cervical cancer, etc. According to the estimate by the Wahington State Department of Health, the prevalence of genital HPV is becoming more and more common, with 14 million newly Americans contracting the virus annually and 79 million Americans currently suffering from HPV infection.

Future Market Scenario (2024 - 2031F)

The growing need to address a variety of symptoms that occur due to the HPV strains, especially genital warts, is driving the market growth. With the advent of new and improved technologies and well researched new drugs and vaccines that are available to everyone, the market will surely see expansion. Treatments like that of laser and surgery are also growing in popularity. They are expensive but because they provide quicker and better results, people are opting for laser despite its high cost. Global healthcare governing bodies are also launching several awareness campaigns to increase awareness related to genital warts among the general population in emerging countries, which, in turn, is acting as a significant market trend.

Key Players Landscape and Outlook

The global genital warts market is dominated by a few major players. Among the businesses that are presently governing the market shares are Pfizer Inc., Sanofi, Orgenesis biotech company, Teva Pharmaceutical Industries Ltd., Verrica Pharmaceuticals, Merck & Co., Inc, and Cipla Ltd. These companies are dominating the market due to their persistent efforts towards R&D, technological advancements, and reliable quality.

Affinivax, Inc. is a diagnostic biopharmaceutical firm based in Cambridge, Massachusetts. GSK plc agreed to buy it in May 2022 for a cash price of $2.1 billion, with an extra $1.2 billion possible if certain growth goals are met. Leading the charge in creating a cutting-edge pneumococcal vaccination for the future is Affinivax.

Eli Lilly and UNICEF signed a new partnership in September 2021 with the goal of improving health outcomes for 10 million children and adolescents with serious non-communicable diseases (NCDs) by 2025. Lilly has pledged $14.4 million as part of this cooperation to support UNICEF's ongoing initiatives in particular nations targeted at reducing NCD risk factors.

Show more
Product Code: MX11093

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Genital Warts Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Drug Type
    • 4.2.1. Imiquimod
    • 4.2.2. Podophyllin and Podofilox
    • 4.2.3. Trichloroacetic acid
    • 4.2.4. Sine catechins
    • 4.2.5. Isotretinoin
    • 4.2.6. Others
  • 4.3. By Treatment
    • 4.3.1. Cryotherapy
    • 4.3.2. Laser removal
    • 4.3.3. Surgical removal
    • 4.3.4. Topical treatment
  • 4.4. By Route of Administration
    • 4.4.1. Oral
    • 4.4.2. Parenteral
  • 4.5. By End-user
    • 4.5.1. Hospitals
    • 4.5.2. Dermatology Centers
    • 4.5.3. Research Centers
    • 4.5.4. Others
  • 4.6. By Region
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia-Pacific
    • 4.6.4. South America
    • 4.6.5. Middle East and Africa
  • 4.7. By Company Market Share (%), 2023

5. Global Genital Warts Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Drug Type
      • 5.1.2.1. Imiquimod
      • 5.1.2.2. Podophyllin and Podofilox
      • 5.1.2.3. Trichloroacetic acid
      • 5.1.2.4. Sine catechins
      • 5.1.2.5. Isotretinoin
      • 5.1.2.6. Others
    • 5.1.3. By Treatment
      • 5.1.3.1. Cryotherapy
      • 5.1.3.2. Laser removal
      • 5.1.3.3. Surgical removal
      • 5.1.3.4. Topical treatment
    • 5.1.4. By Route of Administration
      • 5.1.4.1. Oral
      • 5.1.4.2. Parenteral
    • 5.1.5. By End-user
      • 5.1.5.1. Hospitals
      • 5.1.5.2. Dermatology Centers
      • 5.1.5.3. Research Centers
      • 5.1.5.4. Others
    • 5.1.6. United States*
      • 5.1.6.1. Market Size & Forecast
      • 5.1.6.1.1. By Value
      • 5.1.6.1.2. By Volume
      • 5.1.6.2. By Drug Type
      • 5.1.6.2.1. Imiquimod
      • 5.1.6.2.2. Podophyllin and Podofilox
      • 5.1.6.2.3. Trichloroacetic acid
      • 5.1.6.2.4. Sine catechins
      • 5.1.6.2.5. Isotretinoin
      • 5.1.6.2.6. Others
      • 5.1.6.3. By Treatment
      • 5.1.6.3.1. Cryotherapy
      • 5.1.6.3.2. Laser removal
      • 5.1.6.3.3. Surgical removal
      • 5.1.6.3.4. Topical treatment
      • 5.1.6.4. By Route of Administration
      • 5.1.6.4.1. Oral
      • 5.1.6.4.2. Parenteral
      • 5.1.6.5. By End-user
      • 5.1.6.5.1. Hospitals
      • 5.1.6.5.2. Dermatology Centers
      • 5.1.6.5.3. Research Centers
      • 5.1.6.5.4. Others
    • 5.1.7. Canada
    • 5.1.8. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Drug Type
  • 6.2. By Route of Administration
  • 6.3. By Treatment
  • 6.4. By End-user
  • 6.5. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Pfizer Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Sanofi-Aventis LLC
  • 13.3. Orgenesis Biotech Company
  • 13.4. Teva Pharmaceutical Industries Ltd.
  • 13.5. Verrica Pharmaceuticals
  • 13.6. Merck & Co., Inc
  • 13.7. Cipla Ltd.
  • 13.8. GlaxoSmithKline Plc
  • 13.9. Phio Pharmaceuticals Corp.
  • 13.10. Taro Pharmaceutical Industries Ltd.
  • 13.11. Mylan N.V.
  • 13.12. Bausch Health Companies, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

Show more
Product Code: MX11093

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 3. Global Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 4. Global Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 5. Global Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 6. Global Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 7. Global Genital Warts Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 10. North America Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 11. North America Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 12. North America Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 13. North America Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 14. North America Genital Warts Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 17. United States Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 18. United States Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 19. United States Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 20. United States Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 21. Canada Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 23. Canada Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 24. Canada Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 25. Canada Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 26. Canada Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 27. Mexico Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 29. Mexico Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 30. Mexico Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 31. Mexico Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 32. Mexico Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 35. Europe Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 36. Europe Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 37. Europe Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 38. Europe Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 39. Europe Genital Warts Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 42. Germany Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 43. Germany Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 44. Germany Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 45. Germany Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 46. France Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 48. France Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 49. France Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 50. France Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 51. France Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 52. Italy Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 54. Italy Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 55. Italy Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 56. Italy Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 57. Italy Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 58. United Kingdom Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 60. United Kingdom Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 61. United Kingdom Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 62. United Kingdom Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 63. United Kingdom Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 64. Russia Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 66. Russia Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 67. Russia Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 68. Russia Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 69. Russia Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 70. Netherlands Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 72. Netherlands Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 73. Netherlands Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 74. Netherlands Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 75. Netherlands Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 76. Spain Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 78. Spain Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 79. Spain Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 80. Spain Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 81. Spain Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 82. Turkey Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 84. Turkey Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 85. Turkey Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 86. Turkey Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 87. Turkey Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 88. Poland Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 90. Poland Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 91. Poland Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 92. Poland Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 93. Poland Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 94. South America Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 96. South America Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 97. South America Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 98. South America Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 99. South America Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 100. South America Genital Warts Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 103. Brazil Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 104. Brazil Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 105. Brazil Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 106. Brazil Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 107. Argentina Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 109. Argentina Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 110. Argentina Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 111. Argentina Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 112. Argentina Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 113. Asia-Pacific Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 115. Asia-Pacific Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 116. Asia-Pacific Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 117. Asia-Pacific Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 118. Asia-Pacific Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 119. Asia-Pacific Genital Warts Market Share (%), By Country, 2017-2031F
  • Figure 120. India Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 122. India Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 123. India Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 124. India Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 125. India Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 126. China Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 128. China Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 129. China Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 130. China Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 131. China Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 132. Japan Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 134. Japan Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 135. Japan Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 136. Japan Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 137. Japan Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 138. Australia Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 140. Australia Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 141. Australia Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 142. Australia Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 143. Australia Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 144. Vietnam Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 146. Vietnam Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 147. Vietnam Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 148. Vietnam Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 149. Vietnam Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 150. South Korea Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 152. South Korea Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 153. South Korea Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 154. South Korea Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 155. South Korea Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 156. Indonesia Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 158. Indonesia Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 159. Indonesia Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 160. Indonesia Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 161. Indonesia Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 162. Philippines Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 164. Philippines Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 165. Philippines Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 166. Philippines Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 167. Philippines Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 168. Middle East & Africa Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 170. Middle East & Africa Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 171. Middle East & Africa Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 172. Middle East & Africa Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 173. Middle East & Africa Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 174. Middle East & Africa Genital Warts Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 177. Saudi Arabia Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 178. Saudi Arabia Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 179. Saudi Arabia Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 180. Saudi Arabia Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 181. UAE Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 183. UAE Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 184. UAE Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 185. UAE Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 186. UAE Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 187. South Africa Genital Warts Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Genital Warts Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 189. South Africa Genital Warts Market Share (%), By Drug Type, 2017-2031F
  • Figure 190. South Africa Genital Warts Market Share (%), By Treatment, 2017-2031F
  • Figure 191. South Africa Genital Warts Market Share (%), By Route of Administration, 2017-2031F
  • Figure 192. South Africa Genital Warts Market Share (%), By End-user, 2017-2031F
  • Figure 193. By Drug Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!